ValueAct’s Ubben To Join Valeant’s Board; Valeant Shares Rise 3%

ValueAct is back on Valeant’s (VRX) board. The drug company, now partnered with hedge fund icon Bill Ackman in a hostile takeover campaign against Allergan (AGN), announced Thursday morning that Jeffrey Ubben, ValueAct’s founder and CEO, will join its board on Oct. 1. Ubben is taking the seat vacated by ValueAct’s president, Mason Morfit, earlier [...]